CJC-1295 No DAC & Ipamorelin: Research Hormone Panel Tracking

In the published research literature, CJC-1295 without DAC and ipamorelin are studied against growth-hormone-axis readouts — serial GH sampling over time, plus IGF-1 and its binding proteins as integrated downstream markers. Panel tracking, in that context, simply means repeated structured measurement of those markers across a study window rather than a single snapshot. For a business buying these compounds at wholesale, the operational takeaway is narrower and more useful: any panel is only as reliable as the material behind it, and identity, purity, and lot-to-lot consistency are the variables a purchaser can actually verify before the first order ships.

This page is written for wholesale buyers — med spa owners, clinic operators, telehealth founders, and resellers building a catalog. Everything below concerns research-use-only compounds and the sourcing decisions around them. It is not dosing guidance, preparation guidance, or a description of use in people.

What these two compounds are, and what the research record measures

CJC-1295 without DAC is a modified fragment of growth hormone-releasing hormone. The "no DAC" designation matters analytically: it lacks the drug affinity complex that extends circulating time in the DAC-modified version, so the two are distinct molecules with distinct molecular weights and distinct chromatographic signatures. They are not interchangeable on a certificate of analysis, and a COA that doesn't make the distinction explicit is telling you something about the lab that produced it.

Ipamorelin is a pentapeptide studied as a selective agonist at the growth hormone secretagogue receptor — the receptor family ghrelin acts on. Because it engages a different receptor pathway than a GHRH analog does, the two compounds appear together throughout secretagogue research as a way of probing separate inputs into the same axis.

What gets measured in that literature is fairly consistent. Growth hormone release is pulsatile, so studies rarely rely on one timepoint; research designs generally use timed serial sampling, and studies commonly report IGF-1 as a slower-moving integrated marker, sometimes alongside IGF binding protein measurements. In vitro work adds receptor-level and secretory-response assays in pituitary cell models. Research suggests these readouts are used precisely because they smooth out the noise of pulsatile release — but they cannot smooth out noise introduced by the compound itself.

That is the whole argument for treating sourcing as a data problem rather than a procurement problem.

Why compound variability becomes measurement variance

If purity drifts between lots, the independent variable in any tracked panel isn't actually fixed. Several analytical realities drive that drift, and none of them are exotic:

Synthesis-related impurities. Solid-phase peptide synthesis can leave truncated sequences, deletion peptides, and oxidation products behind. These co-elute close to the target peak and are exactly what an HPLC chromatogram exists to reveal. A stated purity percentage with no chromatogram attached is a number you cannot audit.

Identity confirmation. Purity answers "how much of this vial is one substance." It does not answer "which substance." Mass spectrometry answers the second question, and for two compounds as commonly confused as CJC-1295 with and without DAC, identity confirmation is not optional diligence.

Net peptide content. Lyophilized peptides are salts, and the gross weight in a vial is not entirely peptide. Counterion and residual moisture content mean labeled weight and net peptide weight can diverge. Where a supplier reports net peptide content, comparisons across lots become meaningful; where it doesn't, they don't.

Contamination-related testing. Bioburden, endotoxin, and residual solvent assays are the categories that tend to be quietly skipped, because they cost money and rarely get asked about.

A buyer stocking these compounds for a research customer base inherits every one of these variables. When a downstream researcher sees unexplained variance across a tracked panel, the vial is one of the first places a competent reviewer will look — and "we buy from a supplier who publishes COAs" is a far better answer than a shrug.

Reading a certificate of analysis like a data question

Most wholesale buyers look at a COA to confirm a purity figure and move on. The document is more useful read as a set of questions.

Does the lot number on the certificate match the lot printed on the vial you received? A generic certificate representing "typical" results is a marketing document, not a batch record. Is the chromatogram included, or only a summary line? Is the analysis dated, and does it identify the method? Is identity confirmed independently of purity? And critically — can you access the certificate before you buy, without asking, without a fee, and without a sales conversation?

That last question separates suppliers more cleanly than any other. Some operators in this category treat lab results as a gated asset, supplied only after purchase or bundled as a paid add-on. Others publish unverifiable claims — a purity number with no document behind it, or a reference to "third-party tested" with no lab named and no report reachable. Neither practice is illegal and neither is universal, but both shift the verification burden onto you at exactly the moment you have the least leverage.

A verification checklist to run before any supplier gets an order

Run this before price enters the conversation. A supplier who clears the first six rows and prices slightly higher is usually the cheaper decision once you account for the orders you won't have to explain away later.

Continuity, the variable most buyers underestimate

The first order is easy. The tenth is where wholesale relationships actually get tested.

If you are stocking shelves or building a catalog, your customers' work depends on the same material being available in three months. Supply gaps force substitutions, substitutions introduce new lots from new sources, and new sources reintroduce every variable above. Ask a prospective supplier directly how they handle restock timing, whether they will tell you when a lot changes, and whether historical COAs stay accessible after a lot sells through. Those answers predict the next two years of the relationship far better than an opening price does.

Transparent pricing belongs in the same conversation. Quote-only programs make catalog planning guesswork, because you cannot model a category you have to negotiate for each time. Published tiering lets you decide what to carry and at what depth without a phone call.

Where the legal and licensing questions belong

These are research-use-only compounds. They are not FDA-approved drugs, and nothing about buying them wholesale should be read as clearance to do anything beyond research applications. Beyond that, the honest answer for a business buyer is that the rules are not a settled backdrop you can look up once.

Treat this as a list of questions to bring to your own attorney and, where relevant, your state board — not as conclusions. How does your jurisdiction characterize the resale of research-use-only materials by a business like yours? What licensing, registration, or business-entity requirements attach to your specific model? How must inventory be labeled and records retained? What restrictions apply to how you describe these compounds in marketing? Does your professional licensure carry obligations independent of your business licensing? Does your insurer's position change with this category in your catalog?

This is informational content, not legal advice, and no supplier — Real Peptides included — can answer those questions for you. Any supplier who tells you the compliance picture is simple is giving you a sales answer to a legal question.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built around removing exactly the verification friction described above.

Compounds are tested to 99%+ HPLC purity, and every batch runs through a 7-panel testing process rather than a single purity check. COAs are publicly verifiable — the reader of this page can pull up lab results and read them before there is any commercial relationship, rather than requesting them after an order, paying for them separately, or taking a purity claim on faith. Orders are fulfilled domestically within 5–7 days.

The Wholesale Partner Program uses a 3-step application, so a qualified business can establish an account without an extended negotiation cycle. Pricing tiers are structured rather than improvised per buyer, which is what makes catalog planning possible.

For buyers working in this specific area, CJC-1295 No DAC 10mg and Ipamorelin 10mg are both catalog items with their own published testing documentation, and Tesamorelin 10mg sits in the same research area for buyers building depth in the growth-hormone-axis category.

What the program does not include is dosing, preparation, or administration guidance in any form. That is not an oversight — these are research-use-only compounds, and a supplier that supplies protocols alongside them is describing a use it has no business describing.

Deciding whether this is the right supply relationship

If your business serves researchers and your customers' results depend on knowing what is in the vial, the sourcing question reduces to whether you can verify the material without trusting anyone. A supplier whose testing documentation is public, batch-specific, and readable before purchase makes that possible. One whose isn't makes every downstream dataset partly an act of faith. Businesses ready to evaluate wholesale terms can review the Wholesale Partner Program application at Real Peptides and work through the checklist above against whatever the current supplier is willing to show.

Related reading across the Real Peptides catalog: the Growth Factor & Tissue Signaling Research collection groups compounds studied in adjacent signaling pathways, the Performance & Recovery Research collection covers a related research category, and widely stocked items such as BPC-157 10mg and TB-500 10mg carry the same batch testing and public COA standard described above.